AbbVie Revs Up The Race To Market In Uterine Fibroids

 
• By Jessica Merrill

AbbVie and Neurocrine submitted an NDA to FDA for elagolix for bleeding associated with uterine fibroids, leading in what is expected to be a competitive market.

Submit; Stack of Documents on white desk and Background. - Image
AbbVie filed elagolix with FDA for bleeding associated with uterine fibroids

More from Immunological

More from Therapy Areas